A challenge in achieving clinical remission in patients with schizophrenia lies in the high rate of antipsychotic discontinuation, often resulting in relapse, characterized by exacerbation of symptomatology, deterioration in functional activities, and the emergence of treatment resistance. Long-acting antipsychotics have been developed to help reduce medication nonadherence and minimize relapse. One of the most widely used of these drugs is paliperidone palmitate, a long-acting injectable (LAI) formulation of paliperidone (an active metabolite of risperidone).
{"title":"Real-world usage of paliperidone palmitate injection","authors":"Y. W. Francis Lam Pharm.D., FCCP","doi":"10.1002/pu.31322","DOIUrl":"https://doi.org/10.1002/pu.31322","url":null,"abstract":"<p>A challenge in achieving clinical remission in patients with schizophrenia lies in the high rate of antipsychotic discontinuation, often resulting in relapse, characterized by exacerbation of symptomatology, deterioration in functional activities, and the emergence of treatment resistance. Long-acting antipsychotics have been developed to help reduce medication nonadherence and minimize relapse. One of the most widely used of these drugs is paliperidone palmitate, a long-acting injectable (LAI) formulation of paliperidone (an active metabolite of risperidone).</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Study documents risk of thyroid, kidney complications from lithium treatment","authors":"","doi":"10.1002/pu.31329","DOIUrl":"https://doi.org/10.1002/pu.31329","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Among U.S. adults aged 18 to 64 who reported using prescription stimulant medications, around one-quarter reported stimulant misuse and 9% reported stimulant use disorder, according to a new study. Stimulant misuse and stimulant use disorder were substantially more common among individuals using amphetamines than among those using methylphenidate.
{"title":"Data on prescription stimulant misuse suggest need for closer screening","authors":"","doi":"10.1002/pu.31323","DOIUrl":"https://doi.org/10.1002/pu.31323","url":null,"abstract":"<p>Among U.S. adults aged 18 to 64 who reported using prescription stimulant medications, around one-quarter reported stimulant misuse and 9% reported stimulant use disorder, according to a new study. Stimulant misuse and stimulant use disorder were substantially more common among individuals using amphetamines than among those using methylphenidate.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Study shows improved schizophrenia negative symptoms with xanomeline-trospium","authors":"","doi":"10.1002/pu.31318","DOIUrl":"https://doi.org/10.1002/pu.31318","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 6","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143884183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Weekly doses of the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide resulted in reduced alcohol craving relative to placebo in adults with alcohol use disorder (AUD), a 9-week randomized trial has found. Use of semaglutide also resulted in improvement in some but not all alcohol use outcomes compared with placebo. Study results were published online Feb. 12. 2025, in JAMA Psychiatry.
{"title":"Weekly semaglutide reduces craving in adults with alcohol use disorder","authors":"","doi":"10.1002/pu.31307","DOIUrl":"https://doi.org/10.1002/pu.31307","url":null,"abstract":"<p>Weekly doses of the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide resulted in reduced alcohol craving relative to placebo in adults with alcohol use disorder (AUD), a 9-week randomized trial has found. Use of semaglutide also resulted in improvement in some but not all alcohol use outcomes compared with placebo. Study results were published online Feb. 12. 2025, in <i>JAMA Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 6","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143884141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Age an important variable in response to antidepressants","authors":"","doi":"10.1002/pu.31312","DOIUrl":"https://doi.org/10.1002/pu.31312","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 6","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143884144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"N-acetylcysteine alone not efficacious for youths with cannabis use disorder","authors":"","doi":"10.1002/pu.31315","DOIUrl":"https://doi.org/10.1002/pu.31315","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 6","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143884106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"GLP-1s did not increase suicide risk in patients with type 2 diabetes","authors":"","doi":"10.1002/pu.31313","DOIUrl":"https://doi.org/10.1002/pu.31313","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 6","pages":"6-7"},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143884136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A cohort study based on data in Sweden has found that lithium was the only medication treatment associated with significantly reduced risk of depression-related hospitalization in patients with bipolar disorder. More commonly used antidepressant therapy was associated with increased risk of depression-related hospitalization.
{"title":"Study highlights benefit of lithium in preventing bipolar depression-related hospitalization","authors":"","doi":"10.1002/pu.31311","DOIUrl":"https://doi.org/10.1002/pu.31311","url":null,"abstract":"<p>A cohort study based on data in Sweden has found that lithium was the only medication treatment associated with significantly reduced risk of depression-related hospitalization in patients with bipolar disorder. More commonly used antidepressant therapy was associated with increased risk of depression-related hospitalization.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 6","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143884143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号